Allworth Financial LP Sells 91,375 Shares of Bristol Myers Squibb Company $BMY

Allworth Financial LP lowered its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 41.4% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 129,525 shares of the biopharmaceutical company's stock after selling 91,375 shares during the period. Allworth Financial LP's holdings in Bristol Myers Squibb were worth $7,463,000 as of its most recent filing with the SEC.

Other large investors also recently added to or reduced their stakes in the company. California State Teachers Retirement System lifted its position in Bristol Myers Squibb by 5,484.7% in the second quarter. California State Teachers Retirement System now owns 185,255,963 shares of the biopharmaceutical company's stock valued at $10,674,449,000 after purchasing an additional 181,938,762 shares during the last quarter. Norges Bank bought a new position in shares of Bristol Myers Squibb in the fourth quarter worth approximately $1,947,272,000. Primecap Management Co. CA purchased a new position in shares of Bristol Myers Squibb in the second quarter worth $1,436,115,000. Legal & General Group Plc bought a new stake in Bristol Myers Squibb during the 2nd quarter valued at $980,862,000. Finally, AQR Capital Management LLC raised its holdings in Bristol Myers Squibb by 172.6% during the 4th quarter. AQR Capital Management LLC now owns 25,796,905 shares of the biopharmaceutical company's stock valued at $1,391,485,000 after buying an additional 16,332,924 shares during the last quarter. Hedge funds and other institutional investors own 76.41% of the company's stock.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Promising arlo-cel multiple myeloma results: Bristol Myers reported positive topline results from the registrational Phase 2 QUINTESSENTIAL trial of arlocabtagene autoleucel, or arlo-cel, a potential first-in-class GPRC5D-directed CAR-T therapy. The results could strengthen BMY’s position in heavily pretreated multiple myeloma and expand its growth pipeline. Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial
• Positive Sentiment: Pipeline diversification opportunity: Analysts characterized the arlo-cel data as a potentially important addition to Bristol Myers’ cell-therapy portfolio. Success could eventually provide another commercial product to offset patent-expiration and competitive pressures affecting parts of the company’s existing portfolio. Will the Recent Pipeline Progress Boost BMY’s Portfolio Expansion?
• Neutral Sentiment: SOTYKTU growth potential: An industry report sees additional opportunities for BMY’s SOTYKTU in earlier-line treatment, injection-averse patients and new immune-mediated indications. The report is commercially supportive but does not represent a new company announcement or regulatory approval. SOTYKTU Clinical, Regulatory and Commercial Intelligence Report 2026
• Negative Sentiment: CAR-T safety concerns are weighing on the sector: Novartis paused eight experimental CAR-T trials after three patient deaths linked to severe immune reactions. Although the issue involves Novartis, it may increase investor scrutiny of cell-therapy safety, development costs and regulatory risks for BMY’s arlo-cel program. Could Bristol-Myers Squibb Outperform Novartis as CAR-T Safety Concerns Shake the Sector?
• Negative Sentiment: Investors initially sold the news: Reports indicate BMY shares moved lower despite the arlo-cel trial success, suggesting investors may be taking profits or focusing on unanswered questions around safety, approval timing and the therapy’s eventual commercial potential. Bristol-Myers Squibb Stock Heads Into the Open After a 3.2 Percent Drop

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on BMY shares. Citigroup reissued a "neutral" rating and issued a $70.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, August 3rd. Sanford C. Bernstein raised shares of Bristol Myers Squibb from a "market perform" rating to an "outperform" rating in a research note on Wednesday, August 5th. Weiss Ratings upgraded shares of Bristol Myers Squibb from a "hold (c+)" rating to a "buy (b-)" rating in a report on Tuesday, August 18th. Royal Bank Of Canada raised their target price on Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a "sector perform" rating in a research note on Friday, July 31st. Finally, Truist Financial restated a "buy" rating and set a $70.00 price target (up from $65.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Bristol Myers Squibb has an average rating of "Moderate Buy" and an average target price of $66.06.

Insiders Place Their Bets

In other news, SVP Phil M. Holzer sold 500 shares of the business's stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the sale, the senior vice president directly owned 16,862 shares of the company's stock, valued at $1,138,185. The trade was a 2.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 0.05% of the company's stock.

Bristol Myers Squibb Stock Down 0.4%

Shares of NYSE:BMY opened at $64.46 on Thursday. The firm has a market capitalization of $131.68 billion, a P/E ratio of 14.20, a P/E/G ratio of 0.31 and a beta of 0.23. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. The stock has a 50 day moving average price of $63.39 and a 200-day moving average price of $60.03. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $68.64.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The company had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. During the same period in the previous year, the company posted $1.46 earnings per share. The firm's revenue was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, equities research analysts anticipate that Bristol Myers Squibb Company will post 6.95 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 3.9%. The ex-dividend date of this dividend was Thursday, July 2nd. Bristol Myers Squibb's dividend payout ratio (DPR) is 55.51%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its portfolio includes therapies for cancer, blood disorders, cardiovascular disease, immune-mediated conditions and psychiatric disorders. Key products include Opdivo and Yervoy for oncology, Eliquis for reducing the risk of stroke and systemic embolism, Revlimid for certain blood cancers, and several other specialty medicines.

The company serves patients and healthcare providers in markets around the world, with operations and commercial activities spanning North America, Europe, Asia-Pacific and other international regions.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.